Please note: The COVID-19 SIG is no longer operational.
Purpose
To provide a forum for sharing experiences of statistical and methodological issues relating to clinical trials impacted by COVID-19, clinical trials investigating new treatments for COVID-19 and diagnostic/antibody tests for COVID-19.
Objectives
Who we are
Name | Company/Institution |
James Bell | BI |
Lars Endahl | Novo Nordisk |
Chrissie Fletcher (Co-Chair) | GSK |
Christine Hicking | Merck |
Achim Guettner | Novartis |
Khadija Rantell | MHRA |
Andrea Schulze | Bayer |
Tri Tat | CROS NT |
Marcel Wolbers | Roche |
David Wright (Co-Chair) | AstraZeneca |